Triapten en es it fr

Triapten Brand names, Triapten Analogs

Triapten Brand Names Mixture

  • No information avaliable

Triapten Chemical_Formula


Triapten RX_link

Triapten fda sheet

Triapten msds (material safety sheet)

Triapten MSDS

Triapten Synthesis Reference

Noren, Jan O.; et al., J.Med.Chem. 26(2) 264-270(1983)

Triapten Molecular Weight

126.005 g/mol

Triapten Melting Point

88.06 oC

Triapten H2O Solubility


Triapten State


Triapten LogP

No information avaliable

Triapten Dosage Forms


Triapten Indication

For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Triapten Pharmacology

Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro.

Triapten Absorption

Poorly absorbed after oral administration (bioavailability from 12 to 22%).

Triapten side effects and Toxicity

Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment.

Triapten Patient Information

Triapten Organisms Affected

Human herpes viruses